Top Story

Morning Read: Novartis launches new portfolio of meds for low-income countries

Novartis has now launched “Novartis Access” – which will be a portfolio of affordable medicines used to treat diseases in low-income countries.


Novartis has now launched “Novartis Access” – which will be a portfolio of affordable medicines used to treat diseases in low-income countries. — Novartis

GE Healthcare will take a “startup approach” in its new $300 million emerging markets fund. – MassDevice


Your mandatory Martin Shkreli fix:

  • Turing Pharmaceuticals has been kicked out of BIO. “The company and its leadership do not reflect the commitment to innovation and values that are at the core of BIO’s reputation and mission.” – FierceBiotech
  • Shkreli’s done. But biotech has to clean up the mess. – FierceBiotech
  • Republicans will warm to drug-pricing reform in five to 10 years. – Xconomy
  • Donald Trump: “I thought it was disgusting what he did.” – The Hill

Penumbra hits its IPO mark, clears $125 million in its IPO. – MassDevice

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Israeli medical device company ElastiMed has raised $1 million. It is developing a new device to treat Chronic Venous Insufficiency and prevent Deep Venous Thrombosis. – PRNewswire

Stemina Biomarker Discovery has launched a 1,500-patient study of its experimental test to diagnose children with autism spectrum disorder. – Xconomy

The FDA published a warning letter it sent to NSC Pearson over issues with the company’s Quotient ADHD being marketed as a consumer device to treat ADHD without the proper clearance. — MassDevice


Hospital CEOs sometimes call it quits unexpectedly – here are some reasons why. — Becker’s Hospital Review

Patient safety experts say the Institute of Medicine’s new report on reducing diagnostic errors, “Improving Diagnosis in Health Care,” is a “major milestone” in the effort to improve diagnoses, save lives and advance care. — Fierce Healthcare


An entertaining exchange between TechCrunch and Vinod Khosla at Disrupt: “Because you writers like headlines, I’ll repeat the headlines from last year. I don’t think 90% of VCs add any value. 70% of them actually add negative value that gets tweeted a lot, so it’s good for media.” – Business Insider

The FTC fined Carrot Neurotechnology $150,000 for its Ultimeyes mobile app that claims to improve users’ eyesight without scientific evidence to support those claims. The “scientific research” was written by one of the company owners.  — HealthcareDive

A researcher at Florida Atlantic University has received a $166,935 grant from the National Science Foundation to develop a smartphone-connected test to be used by people with sickle cell disease. — Mobihealthnews


Hillary Clinton is promising to “build on” Obamac are with new proposals that would crack down on insurers to limit premium hikes and halt rising out-of-pocket healthcare costs. — The Hill


A toilet college is set to open in India. That’s right. A toilet college. The effort is designed to increase sanitation and education in the country – one in which people reportedly have more access to cellphones than toilets. — Forbes

Photo: Novartis headquarters from Flickr user Michael Layefsky